Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 5/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30823623 | 0.78 | TSHR (0.38) | TSHRALDH1A1TP53 | |
| SCHEMBL23300869 | 0.78 | TSHR (0.38) | TSHRALDH1A1TP53 | |
| SCHEMBL552731 | 0.75 | — | — | |
| SCHEMBL19879326 | 0.73 | TSHR (0.40) | TSHRALDH1A1MAPK1SLC7A5ANPEP | |
| SCHEMBL6889643 | 0.73 | TSHR (0.40) | TSHRALDH1A1MAPK1SLC7A5ANPEP | |
| SCHEMBL7053011 | 0.73 | — | — | |
| SCHEMBL6720278 | 0.73 | TSHR (0.40) | TSHRALDH1A1MAPK1SLC7A5ANPEP | |
| SCHEMBL24898725 | 0.72 | — | — | |
| SCHEMBL1934957 | 0.71 | TP53 (0.39) | TSHRCYP3A4NFKB1TP53 | |
| SCHEMBL776734 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110236400-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION | 2011-09-29 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | TSHR 4300/4885ALDH1A1 1242/4885MAPK1 2932/4885 |
| US-20110236400-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, APP | TSHR 1740/4885ALDH1A1 100/4885MAPK1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.